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Summary Bladders of anaesthetised mice were illuminated with laser light of 630 nm at 24 h after intra-
peritoneal administration of the photosensitiser Photofrin 11 (10 mg kg-'). A range of light doses, at a power
setting of 100 mW, was delivered intravesically by a fibre optic inserted into the centre of the bladder via the
urethra. Functional bladder damage was assessed from increases in urination frequency and the presence of
haematuria at I to 26 weeks after treatment. Whole bladder illumination with incident light doses exceeding
18.75 J cm-2 caused extensive oedema, haemorrhage and necrosis of the bladder wall and mice had to be
sacrificed within 24 h. PDT with incident light doses of 3.75 to 15.0 J cm 2 caused haematuria and increased
urination frequency during the first week in nearly all mice, but there was complete functional recovery by 6 to
10 weeks after doses of up to 7.5 J cm-2. Recovery was slower after higher doses and up to 50% of mice still
had some increased urination frequency at 10 weeks after > 11.25 J cm-2, although haematuria was rare at
this time. Histologically, early damage (one day after PDT) consisted of epithelial sloughing, submucosal
oedema, fibrin imbibition, vascular extasia and, rarely, thrombosis. Doses exceeding 7.5 Jcm-2 were often
associated with foci of necrosis. In some instances, necrosis was complicated by bacterial infection, resulting in
an acute transmural inflammation with a tendency to suppuration. After doses of up to 11.25 J cm-2 there was
a gradual recovery and only a mild degree of fibrosis of the bladder wall (with some increase in vascularity)
remained at 6 months.
Photodynamic therapy (PDT) is a promising alternative
treatment for small superficial tumours in sites where ade-
quate local surgery is difficult (e.g. obstructive lesions of the
upper airways and multifocal bladder cancer). The basic
principle of PDT consists of systemic administration of a
photosensitising drug, followed by local illumination of the
tumour with light of suitable wavelength to excite the sen-
sitiser. In nearly all clinical trials performed to date,
haematoporphyrin derivative (HPD), or the more purified
Photofrin II, has been used as the photosensitiser in com-
bination with laser light of 625-630nm delivered to the
tumour site via optical fibres.
The haematoporphyrins are non toxic in the absence of
light but they are activated by light of a wavelength corres-
ponding to one of the absorption peaks from the compound.
In its excited state the haematoporphyrin molecule can
interact directly with molecular oxygen to generate singlet
oxygen, or with a biomolecular substrate to generate free
radicals (Boegheim, 1988; Gomer et al., 1988; Davila &
Harriman, 1989); singlet oxygen has been identified as the
most important damaging species. In vivo, the primary target
appears to be the vascular endothelium, with secondary
ischaemic cell death occurring as the result of vascular con-
striction and occlusion (e.g. Bugelski et al., 1981; Star et al.,
1984; 1986; Henderson et al., 1985; Bown et al., 1986).
Photodynamic therapy was first used for the treatment of
human bladder cancer in 1976 (Kelly & Snell, 1976) but the
efficacy of tumour destruction was limited by the light
sources available at that time (transurethral illumination with
white light). With the advent of fibre optics, transurethral
illumination with laser light has become possible and PDT
now appears to be a promising alternative to the use of
transurethral resection (TUR) for the treatment of superficial
bladder cancer, including carcinoma in situ, CIS (Hisazumi et
al., 1983; Benson, 1985; Jocham, 1987). The early trials
employed direct illumination of individual bladder tumours,
which gave a local response in up to 80% of patients
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(Jocham, 1987). The long term results were, however, not
significantly better than for TUR. Due to the multifocal
nature of superficial bladder cancer, it is probably better to
treat the entire bladder mucosa with uniform illumination
(integral PDT). Integral PDT can be achieved by instilling a
light scattering medium into the bladder (Jocham et al., 1984;
Jocham, 1987) or with the use of special isotropic light
sources with a diffuser 'light bulb' tip (Benson, 1985; Nseyo
et al., 1985; Star et al., 1987; Marijnissen et al., 1989).
Preliminary results from ongoing clinical studies indicate a
good response, particularly for CIS. However, follow-up of
patients treated with whole bladder illumination PDT is still
relatively short and there is a lack of information regarding
long term normal tissue toxicity. Many aspects of PDT, such
as optimal timing of light delivery and optimal light and
sensitiser doses, have still to be defined to achieve a good
tumour response without unacceptable bladder damage.
The purpose of the present study was to study the damage
to normal bladder after photodynamic therapy in a mouse
model. In particular, the degree of recovery from acute func-
tional and histological damage was followed for up to 6
months, since persistent functional impairment would limit
the clinical usefulness of the treatment. In these experiments
the influence of increasing light dose (applied 24 h after a
constant photosensitiser dose) was studied. Results from
experiments varying the sensitiser dose and time of adminis-
tration will be reported separately.
Methods
Photosensitiser
Female mice of the strain C3H/Hen Af-nu+, weighing 24 to
30g (aged 12 to 16 weeks) were used. In these experiments
Photofrin II was given intraperitoneally (i.p.), at a dose of
10mgkg-', approximately 24h before bladder illumination.
The drug was provided free of charge, by Lederle, The
Netherlands, as a freeze dried preparation which was dis-
solved in 5% dextrose to a concentration of2.0 mg ml-'. The
stock solution of Photofrin II was then divided into 3 ml
aliquots and stored in the dark at - 20°C until required
(stock solutions were thawed and brought to room
temperature once only before injection). All mice were kept
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in subdued lighting for 1 week after injection of the photo-
sensitiser.
Set-upfor intravesical bladder illumination
The bladders of mice were illuminated with laser light
delivered intravesically at 24-30 h after injection of Photo-
frin II. The mice were anaesthetised (60 mg kg-' sodium
pentobarbitone) and the bladders emptied of urine with a
catheter (VI90 Venflon 22 G/0.8 mm) and light manual pres-
sure. The anaesthetised mice were taped onto a Perspex plate
and a separate catheter attached to a filling syringe was
inserted. The bladder was then filled with 0.2 ml of either a
1% intralipid solution (light scattering medium used with the
plane cut off light delivery fibre in the initial experiments) or
saline (used with a diffuser bulb fibre in later experiments).
The catheter was inserted to a distance of 15 mm from the
urethral opening. This distance had previously been esti-
mated to place the tip of the fibre at the mid point of a
'standard bladder' filled with 0.2 ml fluid. The light delivery
fibre passed through the specially adapted syringe and
catheter and was positioned so that the fibre tip was at the
end of the catheter in the centre of the fluid filled bladder
(Figure 1). Although every care was taken with the experi-
mental setup it was not possible to determine the exact
position of the fibre within the bladder prior to treatment.
Small displacements in the position of the fibre relative to the
true centre (particularly in the arterio-posterior direction) will
certainly have occurred and must be assumed to contribute
to the variation in biological response observed between
mice.
Light deliveryfibres
In the initial experiments a 500,sm diameter plastic fibre
(BCIO, Bicon) was used for light delivery. This fibre had a
plane cut off tip which was slightly polished before use, but
which essentially delivered light in a forward direction only.
In order to scatter the light more uniformly within the blad-
der, a 1% lipid emulsion was instilled into the bladder. For
later experiments we were able to obtain an isotropic diffuser
bulb fibre (kindly supplied by Dr Brian Henderson, Heriot-
Watt University, Edinburgh). This fibre had a thin quartz
core (98 lsm) with plastic coating (external diameter 125psm)
and an isotropic diffusing bulb tip (500gm diameter) which
delivered light in all directions (angular variation ± 5%).The
bladders were filled with physiological saline for use with this
fibre.
Light source anddoses
For illumination of the bladders, the anaesthetised mice were
inverted with the catheter and fibre in position. Inversion
served two purposes: (a) the intestine dropped downwards
out of the illumination field, (b) the vertical alignment of the
bladder increased the probability of correctly positioning the
fibre in the centre of the bladder. The light delivery fibre was
coupled to a 12W argon laser (Spectra-Physics model 171),
which powered a dye laser (Spectra-Physics model 375) tuned
to 630 nm. A power setting of 100 mW was used and the
output from the fibre tip was checked (in air) before and
after each treatment with an integrating light sphere. The
bladders were filled with 0.2 ml fluid prior to illumination
therefore the calculated surface area of the bladder, assuming
it to be a perfect sphere, should be 165mm2. However, the
bladder is not a perfect sphere and, moreover, small quan-
tities of fluid often leaked during filling. In a representative
sample of 18 mice (not used for the PDT experiments), the
bladder was surgically exposed (under anaesthetic) after
filling with 0.2 ml fluid and the actual size of the bladder was
measured in 3 orthoganol diameters using fine vernier
calipers. The surface area calculated from the geometric
mean radius of these measurements was 134 ± 25 mm2
(± 1 s.d.). This area was used to calculate the incident light
dose (i.e. for a fibre output of 100 mW this represents
75 mW cm-2 at the bladder surface). Illumination times
ranged from 50 s to 4 min and 1Os, which is equivalent to
3.75 J cm-2 to 18.75 J cm-2. All light doses quoted from
Laser linht (IP.f nmi
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Figure 1 Schematic representation of experimental set up for light delivery to the bladder. The catheter is inserted (under
anaesthetic) to a distance of 15mm from the urethral opening. The light delivery fibre passes through the catheter and, after
injection of 0.2 ml saline, the diffusing tip sits at the end of the catheter but does not protrude further into the bladder.886 F.A. STEWART et al.
these experiments refer to the incident exposure dose of non
scattered light only. At least 10 mice were included in most
treatment groups but two groups had only five to six mice.
Control groups of light alone (18.75 J cm-2 and 37.5 J cm-2),
Photofrin II alone (10 mg kg-') and untreated mice were also
included.
Assaysforfunctional bladder damage
Mice were tested for urination frequency and the presence of
haematuria at weekly intervals for the first month and then
monthly until 6 months. Urination frequency tests were car-
ried out over a 24 h test period during which the mice were
placed in individual cages with wire bar floors. There was
free access to food and water during this period and absor-
bant paper was drawn beneath the cages at a speed of
approximately 15 cm per hour. At the end of the test period
the paper was removed and the number of discrete urination
events was counted as previously described (Stewart et al.,
1978; Edrees et al., 1988). The volume of urine produced by
each mouse was also estimated by comparing the area of
each urine spot with a calibration curve for known volumes
of urine. Urination frequency was expressed as the number of
urination events per 24 h and then corrected for the volume
of urine produced per 24 h. This parameter is defined as the
frequency index (spots per ml) and has been described in
detail elsewhere (Stewart et al., 1978; 1991; Stewart 1986).
Results are expressed either as a group mean frequency
index, or as the percentage of mice with a frequency index
greater than twice the mean control value.
The presence of haematuria was determined using standard
Bili labstix. These tests were always carried out between
0.900 h-I1.00 h, by dipping the test strips in fresh urine
samples. Results were scored as positive or negative only,
with no attempt to define the degree of haematuria.
Histology
A few mice from each dose group were sacrificed at 1 day,
1 week and 1 month after PDT (using the plane cut off fibre)
and the bladders examined histologically. All remaining mice
were sacrificed at 6 months and the bladders taken for
histology (plane cut off fibre and isotropic diffuser bulb
fibre). Bladders were excised immediately after sacrifice (by
cervical dislocation), after instillation with 100-200
fixative (ethanol:acetic acid:formaldehyde:saline; 40:5:10:45
v/v). After 24 h in fixative the bladders were transferred to
70% alcohol until they were prepared for histology. The
fixed bladders were bisected longitudinally, embedded in
paraffin wax and cut at 5 gtm (longitudinal sections were
made from the central part of the bladder). Sections were
stained with haematoxylin and eosin and scored blind by our
pathologist (W.J. Mooi).
Results
Survival and weight loss
In initial toxicity studies, small numbers of mice (three to
four per dose group) were treated with light doses of up to
37.5 J cm-2 (using the plane cut off fibre) at 24 h after
10 mg kg-' Photofrin II. All mice in dose groups above
18.75 J cm-2 became clinically ill and were sacrificed over the
period 2 to 9 days after treatment. At post mortem there was
obvious swelling and erythema in the whole pubic area with
evidence of fat necrosis in the immediate vicinity of the
bladder. The bladders were haemorrhagic and oedema of the
uterus and cervix was also seen. There was no sign of
haemorrhage or necrosis of the intestine. All animals treated
with 37.5 J cm-2 alone or Photofrin II alone remained heal-
thy and without significant weight loss.
On the basis of initial toxicity studies, the maximum light
dose delivered to the bladder was subsequently restricted to
< 18.75 J cm-2 non scattered light. In the first experimental
series, using the plane cut offfibre for light delivery, the LDM
was 19.9 ± 3.2 J cm-2 (± 1 s.e.) for illumination of the blad-
der 24 h after 1Omgkg-' Photofrin. In the second experi-
mental series using the diffuser bulb fibre for light delivery
the LD50 was 15.7 ± 2.1 (Table I). Ifmice became clinically ill
this always occurred at 1 to 3 weeks. Post mortem examina-
tion of these animals, which were sacrificed, revealed
epithelial sloughing and haemorrhage and oedema of the
bladder wall. All surviving mice were sacrificed at 6 months
and the bladders were examined histologically. Adhesions
between the bladder and surrounding fat were common,
particularly after doses > 11.25 J cm-2. After these higher
doses, the perivascular fatty tissue often exhibited signs of
necrosis. In one instance there was histological evidence of
advanced interstitial nephritis, presumably caused by ascend-
ing bacterial infection. Mean weight losses of 3 to 6g per
mouse were measured at 1 week after PDT with maximum
tolerated doses. There was recovery to pretreatment weight in
all surviving mice by 5 weeks.
Functional bladder damage
The mean frequency of urination of 10 control animals over
the entire 6 month test periods was 11.2 spots per 24 h (s.d.,
4.2) and the mean urine production was 2.0 ml per 24 h (s.d.
0.8), giving a mean frequency index of 5.6 spotsml-'. Light alone or Photofrin alone did not significantly alter the urina-
tion frequency or urine production. Urine volumes of the
PDT treated mice were usually within the control range but
some mice, particularly in the first 3 weeks after treatment,
produced very small volumes of urine (<0.5 ml in 24h).
This presumably reflected dehydration and general ill health
of these mice, which were excluded from the frequency
analysis since it seemed unlikely that the corresponding fre-
quency index would reflect specific bladder damage.
Following PDT with the plane cut off fibre, there was a
significant increase (P<0.4; Mann-Whitney two sample test)
in the group mean frequency index after all light doses tested
(4.7 to 14J cm-2) at 1 to 2 weeks after treatment, with a
return to control levels by 3 weeks after light doses of
4.7Jcm-2, and within 9 weeks after 9.4Jcm-2. There was
also some recovery from 2 to 16 weeks after 14 J cm 2, but
the urination frequency index remained above control levels
for up to 25 weeks in some animals. The pattern and extent
of functional bladder damage and recovery after PDT using
the plane cut off fibre were essentially the same as for the
isotropic diffuser bulb fibre. The major difference was that a
greater variation between animals was seen using the plane
cut off fibre and results from these experiments are therefore
not discussed in detail.
In experiments using the diffuser bulb fibre for light
delivery, there was a significant increase (P<0.04; Mann-
Whitney two sample test) in the group mean urination fre-
quency index at 1 week after PDT for all light doses and
recovery to control levels within 2 to 6 weeks after doses of
3.75 to 7.5 Jcm2 (Figure 2, top). After higher doses the
urination frequency index remained elevated for some
animals until the end of the testing period, although, because
of the large variation in response between animals, the mean
Table I Mouse survival after PDT
(10mg kg-' Photofrin 24 h before light)
Fibre type Light dose (Jcm-2) Survival
Diffuser bulb 3.75 (10/10) 100%
LD50= 15.7 ± 2.1 7.5 (10/10) 100%
11.25 (10/10) 100%
13.1 (7/11) 64%
15 (2/5) 40%
Plane cut off
LD50 = 19.9 ± 3.2
4.7
9.4
14.1
18.8
LD% calculated by probit analysis ± 1 s.e.
(6/6)
(12/13)
(10/11)
(4/9)
100%
92%
91%
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Figure 2 Time changes in mean urination frequency index ± 1
s.e.m. (top) or percentage of mice with a 2-fold increase in
frequency index (bottom), after PDT using the diffuser bulb fibre
to deliver incident light doses of 3.75 to 13.1 J cm-2. The groups
marked [ ] represent mean results from only five mice, the remain-
ing mice in this group had either died or produced too little urine
for an analysis of frequency index. The shaded area (top panel)
indicates the mean frequency index of control animals ( 1 s.d.)
over the entire testing period of 25 weeks.
frequency index was not significantly different from control.
In the top dose group the mean urination frequency index is
probably an underestimate of the amount of functional blad-
der damage induced, since four out of 11 mice died during
the acute period (1 to 3 weeks) and at least one of the
survivors at each subsequent test produced <0.5 ml urine/
24h and was therefore excluded from the analysis.
The results from urination frequency tests were also ex-
pressed as the percentage of mice with a frequency index of
more than twice control (i.e. > 12 spots per ml). There was a
20% incidence of increased frequency at 1 week after light
doses of 3.75 J cm-2 and a 70 to 100% incidence after doses
of 7.5 to 13.1 J cm-2. By 10 weeks, only 20 to 50% of mice
treated with light doses > 11.25 J cm-2 had an increased
frequency (Figure 2, bottom).
The dose response curves for mean urination frequency
index and the incidence of increased frequency are shown in
Figure 3. There was a clear relationship between light dose
and both the extent of functional bladder damage (mean
frequency index, Figure 3 top) and percentage of mice with a
2-fold increase in frequency index (Figure 3 bottom). Both
the severity and incidence of damage were reduced at 14
weeks compared with 1 week.
The light dose required for a 2-fold increase in urination
frequency index in 50% of the mice (ED50 ± ls.e.) was cal-
culated by probit analysis at each testing time. In the acute
phase (1 week), the ED50 was only 6.2 ± 1.0 Jcm2). but
there was good recovery from the PDT induced damage after
low doses and the estimated ED50 for increased urination
frequency at 10 weeks had increased to 16.8 ± 4.9Jcm2.
From 10 to 26 weeks there was no further change in the ED50
(Figure 4). For comparison, the ED50 values estimated at 1
Figure 3 Dose response curves (at 1 and 14 weeks after PDT)
for group mean frequency index (± 1 s.e.m.) or incidence of
increased frequency relative to controls (probit analysis of mice
with > 12 spots ml-'). Dose groups marked [J contain results
from only five mice, other groups had eight to ten mice.
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Figure 4 Light doses required to give an increased frequency
index (> 12 spots ml-') in 50% of mice were calculated by
probit analysis (± I s.e.). The ED50 increased from 1 to 10
weeks after PDT, with no further change from 10 to 26 weeks.
and 14 weeks after PDT with the plane cut off fibre were
6.5 ± 1.7 and 17.2 ± 5.5 respectively (i.e. no significant
difference between the two fibres).
Haematuria
Haematuria was seen in some animals from all dose groups
during the first week after PDT and the incidence was dose
related. Light alone or Photofrin II alone did not cause
haematuria. In most cases haematuria did not persist beyond
the first week but some responses were also seen at 2 to 4
weeks, and in the highest dose groups up to 25 weeks after
PDT. The cumulative incidence of haematuria during the
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acute period (1 to 4 weeks) and late period (17 to 25 weeks)
is shown in Table II. The ED50 for haematuria during the
acute phase was 7.6 ± 1.0 J cm-2 for diffuser bulb fibre and
6.5 ± 2.3 for the plane cut off fibre (ED50 ± 1 s.e. calculated
by probit analysis).
Histology
Urinary bladders of mice which had received only Photofrin
II or bladder illumination were histologically identical to
those of untreated control mice. The bladder surface was
lined by a smooth or slightly folded layer of transitional
epithelium, below which the lamina propria, consisting of a
small amount of subendothelial loose connective tissue con-
taining thin-walled vessels, was present. In some instances a
muscularis mucosa could be discerned. This and the mus-
cularis propria consisted of smooth muscle cells with a very
small amount of collagen. Some specimens contained a small
amount of adherent fatty tissue, some of which was of the
'brown' (multivacuolated) variety.
One day after treatment, mice receiving Photofrin II and
illumination exceeding 4.7 J cm-2 showed signs of acute
damage, consisting of epithelial sloughing, oedema, fibrin
Table II Incidence of haematuria after PDT (10 mgkg-' Photofrin
24 h before light)
Light dose
(Jcm-2) 1-4 week 17-25 weeks
3.75 (2/10) 20% (0/10) 0%
Diffuser bulb 7.5 (4/10) 40% (0/10) 0%
ED50= 7.6± 1.0 11.25 (7/8) 88% (0/10) 0%
13.1 (6/6) 100% (1/7) 14%
Plane cut off fibre 4.7 (2/7) 29% (0/5) 0%
9.4 (8/11) 73% (0/10) 0%
ED50=6.5± 2.3 14.1 (11/12) 92% (1/10) 10%
18.8 (8/9) 89%
ED50 ± s.e. calculated by probit analysis.
extravasation, dilatation of blood vessels and, rarely, throm-
bosis (Figure 5a). Most cases receiving 11.3 J cm-2 or more
also exhibited areas of frank necrosis of the bladder wall. In
some cases the toxic damage was complicated by bacterial
infection, as evidenced by the presence of large colonies of
bacteria, associated with a dense transmural polymor-
phonuclear inflammatory infiltrate (Figure Sb). Such exten-
sive damage and inflammation of the bladder wall persisted
a
b d
c S
Figure 5 Histological sections of mouse bladder at various intervals after PDT treatment. 5 lam sections, stained with haema-
toxalin Eosin, original magnification x 100. a, One day after PDT, 9.4 J cm-2. The surface epithelial layer is partially detached
from the lamina propria (LP), which exhibits a mild degree of oedema and some fibrin extravasation. b, One week after PDT,
14.1 J cm2. There is focal necrosis of the mucosa (N), and a transmural inflammatory infiltrate (I) indicates acute damage also of
deeper layers. c, Six months after PDT, 9.4 J cm-2. The histology is practically normal; there is a very slight degree of fibrosis of
the lamina propria with pseudopapillary in foldings (P). d, Six months after PDT, 9.4 Jcm2. Distinct fibrosis of the lamina
propria (F) and a darkly-staining focus of calcification (C) within the muscle layer. e, Control bladder with intact epithelium and
large superficial cells (SC) at the luminal surface.
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for at least a week.
Late injury, as assessed after 4 to 25 weeks, consisted
mainly of a mild degree of submucosal fibrosis with a slight
increase in numbers of blood vessels. In some instances there
was probably also some hyperplasia of the muscularis,
although this may in part have been simulated by contraction
or fibrotic shrinkage of the bladder wall. In some instances,
the mucosa exhibited pseudopapillary infoldings, possibly re-
sulting from shrinkage of the prevously oedematous bladder
(Figure 5c). These late signs of damage tended to diminish
with time; after 6 months, histological abnormalities were
generally minimal, consisting mainly of a slight degree of
fibrosis, although a few specimens (from mice treated with
light doses >9.4 J cm-2) had a more severe degree of fibrosis
which extended into the muscle layer and which could be
associated with calcification (Figure 5d).
Discussion
Clinical interest in the use of photodynamic therapy as an
alternative to TUR with chemotherapy for localised bladder
cancer, particularly CIS, is increasing (Tsuchiya et al., 1983;
Hisazumi et al., 1984; Benson, 1985; Jocham, 1987; Prout et
al., 1987; Shumaker & Hetzel, 1987; Gomer et al., 1989).
Most current trials attempt to illuminate the entire bladder
mucosa as uniformly as possible, since there are often foci of
neoplastic or pre-neoplastic areas which are not visible, and
therefore escape local treatment, but which may progress if
left untreated.
The biological effect of PDT is determined by the energy
absorbed by the photosensitiser in the tissue. For a constant
photosensitiser dose, energy fluence (light dose) is the critical
factor. Light dose consists of primary (non-scattered) light
and scattered light. The doses quoted in this paper represent
only the primary incident light at the bladder surface (cal-
culated on the basis of 100 mW output from the fibre over a
total bladder surface area of 134 mm2; i.e. 75 mW cm-2). The
scattered light dose can only be determined if the optical
properties of the tissue in question are known. These are not
known for mouse bladder but calculations for dog bladder
(Star et al., 1987) show that the total fluence (including
scattered light) is about five times the incident primary light
dose. The ratio between primary and scattered light is weakly
dependent on bladder volume and, assuming the optical pro-
perties of the mouse bladder and surrounding tissue is not
different from that of dog bladder, the total fluence rate of
the mouse bladder surface should be approximately three to
four times the incident light dose (personal communication,
Dr Willem Star, Daniel den Hoed Cancer Center, Rotter-
dam).
When the entire bladder is treated with PDT, some
damage to the normal mucosa is to be expected. Most
patients do indeed develop symptoms of bladder irritability,
frequency, urgency and reduced bladder capacity during the
first 4 weeks after treatment (Benson, 1985; Jocham, 1987;
Harty et al., 1989). Cystoscopy generally reveals oedema and
an exudative reaction in the mucosa. However, in many cases
the reactions are reported as transient with a return to near
normal bladder function within 3 to 5months (Benson, 1985;
Jocham, 1987). Another, more serious, possible side effect of
bladder PDT is vesicouretic reflux and hydronephrosis, which
can develop as a result of decreased bladder capacity and
ureteral obstruction (Harty et al., 1989).
The purpose of our study was to measure the extent and
duration of functional damage and recovery in normal mouse
bladder after PDT with a range of light doses given 1 day
after 10mgkg-' Photofrin II. Our results demonstrated that
increased frequency and haematuria occurred during the first
month after treatment, even with modest incident light doses
(3.75 to 7.5 Jcm-2), but that the severe acute reaction was
transient, with partial or complete recovery (depending on
the light dose) within 5 to 10 weeks. Bladder functional
damage during the acute phase coincided with a histological
picture of submucosal oedema and inflammation with
epithelial sloughing. During the acute phase it is likely that
bacterial infection of the partly denuded bladder mucosa also
contributed to the observed increase in urination frequency.
Animals in the present study were not tested for the presence
of bacteria in the urine but bacterial colonies were visible in
the mucosa of some histology specimens taken during the
first 2 weeks after PDT with high light doses. In a separate
series of mice (unpublished data), the urine was tested for the
presence of nitrates after PDT and nearly all mice treated
with 10 Jcm2 plus Photofrin were positive during the first
month, whereas animals treated with light or Photofrin II
alone were negative. Bacterial infection will contribute to any
inflammation of the bladder wall and oedema and antibiotics
given after PDT could help to limit the acute reactions.
Studies are currently underway to investigate this in our
mouse bladder model. We noted an occasional incidence of
cyst formation in the kidneys of PDT treated mice and, in
one case, a histologically confirmed advanced pyelonephritis.
This may well have been the result of an ascending urinary
tract infection, but ureteral blockage (caused by oedema and
fibrosis) with back pressure may also have played a role.
Since the kidneys were not routinely taken for histology a
higher incidence of renal complication may have occurred
but gone undetected in our experiments.
Despite a severe acute reaction after PDT, the long term
recovery was good and there was only minimal persistent
functional damage (increased urination frequency and
haematuria) after light doses up to 9.4 J cm-2. Some sub-
mucosal fibrosis was seen at 6 months along with mild
vascular damage and pseudopapillary infoldings which may
have been the result of excessive oedema during the acute
phase and subsequent contraction of the bladder.
There have been very few published reports of the effects
of PDT in normal bladder tissue using experimental animal
models (Nseyo et al., 1985; Reed et al., 1989; Pope & Bown,
1991). Nseyo et al. (1985) treated dog bladders with intra-
vesical PDT and examined the tissue histologically at 5 days
after treatment. Whole bladder exposure of light alone
(30 J cm2) produced a slight, generalised oedema in the
epithelium. Light doses of 30 J CM-2 given 3 days after
Photofrin II caused oedema and multiple superficial ulcers.
Haemorrhage was also observed in the lamina propria,
together with focal damage to the muscle layer. No speci-
mens were available of bladders at longer intervals than
5 days, so it is not possible to assess the long term effects of
PDT from this study.
Another study followed the microvascular changes in the
rat bladder during the first hour after PDT (Reed et al.,
1989). Significant reductions in the red blood cell column
diameters of arterioles and venules were found, with evidence
of thrombus formation and blood flow stasis. The vascular
changes were much more marked when light (105 Jcm-2)
was applied at 30 min after Photofrin II than at 2 days. The
authors concluded that for intervals of 48 h or longer
between sensitiser and light any damage to the normal blad-
der was the result of diret photosensitisation in the bladder
wall, whereas the shorter intervals lead to preferential micro-
vascular damage.
The only other study of functional changes in the normal
bladder after PDT was reported by Pope and Bown (1991),
who studied compliance in the rat bladder for up to
3 months after PDT. In these studies, chloraluminium sul-
phonated phthalocyanine was used as the photosensitiser and
20 J cm2 red light (675 nm) was delivered intravesically after
24 h. The treated rats had an initial reduction in bladder
capacity but recovery was rapid (within 2 weeks) after low
sensitiser doses (0.5 mg kg-'). Recovery was much slower
after sensitiser doses of 1.5 mg kg-' combined with
20JCcm2, and some reduced bladder capacity was still evi-
dent at 3 months. These results agree well with those
obtained in the present study and suggest that a severe acute
response occurs after whole bladder PDT which involves
epithelial denudation and submucosal oedema, associated
with increased urination frequency and reduced bladder
capacity. Providing tolerance limits of light and sensitiser890 F.A. STEWART et al.
dose are not exceeded, however, the acute damage heals
rapidly to leave a functional bladder with minimal his-
tological changes within 2 to 3 months of treatment. From
our results with the mouse bladder 'tolerance' is estimated at
about 10 J cm-2 non scattered light for whole bladder
illumination at 24 h after 10 mg kg-' Photofrin II. This
would correspond to absorbed light doses of approximately
35 to 45Jcm-2.
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